Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023
Get featured
Want to get featured in MarketScale Sciences?
Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.
Resilience and Eli Lilly are expanding their strategic partnership, which began in 2023, with a series of substantial investments aimed at bolstering U.S. pharmaceutical manufacturing. The collaboration, marked by a $750 million investment, focuses on increasing the production of Lilly’s KwikPen®, an injectable device used for diabetes and obesity medications. This move aligns with the surging demand for such treatments and aims to strengthen the availability of U.S.-manufactured medicines.
Focused investment in Ohio manufacturing
The investment will enhance Resilience’s manufacturing capabilities in the Cincinnati region, introducing Lilly's KwikPen production to its portfolio. This expansion is expected to create 400 high-skilled jobs, further elevating Resilience's impact in Ohio, where it already employs around 1,000 people across its advanced facilities. Preparation for the site expansion is in progress, with full operations anticipated by early 2027.
“Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States." — William S. Marth, President and CEO of Resilience
The partnership between the two companies has already resulted in over 150 million doses of Lilly’s medications being produced for the U.S. market. By leveraging proven technical capabilities and a steadfast commitment to quality, Resilience and Lilly aim to maintain the highest standards in domestic medicine supply. Edgardo Hernandez, Lilly’s Executive Vice President, highlighted the need for scalability and reliability in meeting the growing demand for complex manufacturing programs.
Strategic partnership and regional growth
This partnership underscores Ohio’s emerging leadership in biomanufacturing, as recognized by Ohio Governor Mike DeWine, who cited Resilience's headquarters move to Blue Ash as evidence of the state's robust life sciences sector. Joining forces with entities like JobsOhio, REDI Cincinnati, and Ohio Life Sciences, Resilience contributes to a thriving pipeline of skilled manufacturing talent. These collaborations are part of broader efforts to sustain and grow the region’s capacity in the life sciences industry.
“Statewide investments in biomanufacturing training are preparing Ohioans for careers with Resilience and other industry leaders seeking growth.” — J.P. Nauseef, JobsOhio President and CEO
As Resilience continues to expand, its relationship with Lilly exemplifies how strategic partnerships can elevate both companies' capabilities while reinforcing the U.S. medicine supply chain. By focusing on disciplined execution and operational excellence, Resilience is establishing itself as a key player in addressing the needs of biopharma innovators and enhancing the U.S.’s role in global pharmaceuticals.
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
